Detalhe da pesquisa
1.
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
Br J Haematol
; 196(5): 1209-1218, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34915592
2.
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma.
Blood Adv
; 4(19): 4802-4811, 2020 10 13.
Artigo
Inglês
| MEDLINE | ID: mdl-33022066
3.
Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease.
Mayo Clin Proc
; 81(9): 1188-94, 2006 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-16970215
4.
Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Am J Nephrol
; 26(2): 149-56, 2006.
Artigo
Inglês
| MEDLINE | ID: mdl-16636531
5.
Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
Curr Med Res Opin
; 22(10): 2023-30, 2006 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-17022861